Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice

The luminal HER2-negative subtype is the dominant variant of metastatic breast cancer; modern combined endocrine therapy with CDK4/6 inhibitors due to significantly change the prognosis of the disease, not only for increasing progression free survival, but also for significantly prolonging the life...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autor: I. V. Kolyadina
Médium: Artigo
Jazyk:Russo
Vydáno: ABV-press 2021-09-01
Edice:Opuholi Ženskoj Reproduktivnoj Sistemy
Témata:
combined endocrine therapy
inhibitors cdk4/6
ribociclib
monaleesa-2
monaleesa-3
monaleesa-7
visceral crisis
On-line přístup:https://ojrs.abvpress.ru/ojrs/article/view/845
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky